Study to Evaluate the Pharmacokinetics, Safety and Tolerability of GSK557296 in Healthy Women Volunteers After Single and Repeat Dosing

10 mg single oral dose. Each subject will receive 2 tablets of 5 mg GSK557296 four times a day (QID).

150 mg single oral dose. Each subject will receive multiple tablets of 25 mg GSK557296 either 2, 3 or 4 times a day.

Dose to be determined as a single dose tablet based on half-life demonstrated in Cohort 1 and Cohort 2.

Dose to be determined by PK of prior doses, based on half-life demonstrated in prior cohorts.